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Abstract
Introduction: Thyroid hormone disorders in patients with chronic kidney disease (CKD) are a result of impaired conversion of T4 to T3. 
The importance of kidneys in thyroid hormones conversion is not fully understood. The activities of different types of iodothyronine 
deiodinases in the kidney structures have not been determined yet. 
The aim of this study was to determine the activity of deiodinase type 1 (D1) and type 2 (D2) in renal cortex and medulla in renal cancer patients.
Material and methods: Samples of renal cortex and medulla (ten patients) or renal cortex alone (13 patients) were taken from kidneys 
resected because of malignant cancer, from a site opposite to the cancer. Resections were performed in the 23 patients (seven female and 
16 male) who were 52–82 years old. The material was stored at –72 oC. 
Results: Activity of D1 in renal cortex was 3.785 ± 2.041 fmol 125I/mg protein/minute and activity of D2 was 0.236 ± 0.125 fmol 125I/mg 
protein/minute. There was a strong positive correlation between D1 and D2 activities in renal cortex (r = 0.890, p < 0.001). Activity of D1 
in renal medulla was 2.157 ± 2.176 fmol 125I/mg protein/minute, and activity of D2 was 0.168 ± 0.095 fmol 125I/mg protein/minute. A posi-
tive correlation between D1 and D2 in renal medulla (r = 0.661, p = 0.038) was observed as well. Activities of D1 in cortex and medulla 
were strongly and positively associated (r = 0.794, p = 0.006), whereas there was no correlation between the activities of D2 in cortex and 
medulla (r = 0.224, p = 0.553).
Conclusions: Results presented in this study suggest that both cortical and medullary D1 and D2 may be involved in thyroid hormone 
metabolism. This finding could be of clinical relevance in patients with impaired renal function.  (Endokrynol Pol 2013; 64 (3): 182–185)
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Streszczenie
Wstęp: Zaburzenia hormonów tarczycy u pacjentów z przewlekłą chorobą nerek (PChN) są wynikiem zaburzeń konwersji T4 do T3. 
Znaczenie nerek w konwersji hormonów tarczycy nie jest w pełni poznane. Działania różnych typów dejodynaz jodotyroninowych 
w strukturach nerek, nie zostały jeszcze określone. 
Celem badań było określenie aktywności dejodynazy typu 1 (D1) i typu 2 (D2) w korze i rdzeniu nerek u chorych z rakiem nerki. 
Materiał i metody: Próbki kory i rdzenia nerek (10 pacjentów) lub tylko samej kory (13 pacjentów) były pobrane z przeciwnego bieguna 
tej samej nerki do guza , z nerek usuniętych z powodu raka. Resekcje wykonano u 23 chorych (7 kobiet i 16 mężczyzn) w wieku 52–82 lat. 
Wyniki: Aktywność D1 w korze nerki wynosiła 3,785 ± 2,041 fmol 125I/mg białka/min., a aktywność D2 wynosiła 0,236 ± 0,125 fmol 125I/
mg białka/min. Znaleziono silną, dodatnią korelację pomiędzy aktywnością D1 i D2 w korze nerki (r = 0,890, p < 0,001). Aktywność D1 
w rdzeniu nerek wynosiła 2,157 ± 2,176 fmol 125I/mg białka /min., a aktywność D2 wynosiła 0,168 ± 0,095 fmol 125I/mg białka/min. Zaob-
serwowano również dodatni związek pomiędzy aktywnością D1 i D2 w rdzeniu nerek (r = 0,661, p = 0,038). Stwierdzono silną dodatnią 
korelację aktywności D1 w korze i rdzeniu (r = 0,794, p = 0,006) oraz brak korelacji aktywności D2 w korze i rdzeniu (r = 0,224, p = 0,553).
Wnioski: Wyniki przedstawionej pracy sugerują, że aktwność dejodynaz 1 i 2 zarówno w korze jak i w rdzeniu nerki może miec 
wpływ na metabolizm hormonów tarczycy. To ustalenie może mieć znaczenie kliniczne dla chorych z upośledzoną funkcją nerek. 
(Endokrynol Pol 2013; 64 (3): 182–185)
Słowa kluczowe: dejodynaza, 5’-dejodynaza jodotyroninowa, hormony tarczycy, nerka, kora, rdzeń
This research was carried out with the approval of the Medical University of Warsaw Bioethics Committee (KB/138/2005, dated 30.06.2005), 
supported by a grant from the Medical University of Warsaw (1WM1/09).
183
Endokrynologia Polska 2013; 64 (3)
PR
A
C
E 
O
RY
G
IN
A
LN
E
Introduction
Thyroid hormone disorders in patients with chronic 
kidney disease (CKD) result from impaired conver-
sion of T4 to T3 leading to decreased T3 levels. The 
importance of kidneys in thyroid hormones conver-
sion is not fully understood. In adult mammals, the 
activity of deiodinases has been identified in the liver, 
kidney, thyroid, pituitary gland, intestines, placenta and 
gonads. The activities of different types of iodothyro-
nine deiodinases in kidney structures have not been 
determined yet. The disorders may be partly explained 
by the absence of renal tissue and decreased activity 
of deiodinases connected with this matter. There are 
significant differences in the course of ‘sick euthyroid 
syndrome’ in patients with CKD and with normal renal 
function in other severe diseases. The concentration 
of rT3 is normal in CKD patients as opposed to other 
patients with this syndrome. 
Determination of deiodinases activity in various 
kidney structures may be useful in explaining thyroid 
hormone disorders and differences between patients 
with CKD and other patients. In various diseases, the 
presence of pro-inflammatory cytokines and acidosis 
may be a key factor affecting hormonal conversion and 
hormonal state [1–4].
The purpose of the study was to determine the activ-
ity of deiodinase type 1 (D1) and type 2 (D2) in renal 
cortex and medulla in renal cancer patients.
Material and methods
Specimens of renal cortex and medulla (ten patients) or 
renal cortex alone (13 patients) were taken from kidneys 
resected because of malignant cancer. The differentiation 
of tissues (cortex or medulla) was performed macro-
scopically by a urologist during kidney resection by taking 
samples. The collection of material from both structures 
was not possible in all patients. Collecting cortex, an outer 
part of the kidney, is easy and has always been possible 
(23 specimens). Examining the renal medulla was performed 
only when there was a macroscopical certainty that it was 
a proper material (ten specimens). The samples were 
taken from a site opposite to the cancer. Resections were 
performed in 23 patients (seven females and 16 males) 
aged 52–82 years. None of the patients was pharmacologi-
cally treated for cancer. The material was stored at –72oC.
Apparatus
Tissues were homogenised using an Ultra-Turrax 
T25 Homogeniser. Radioactivity was measured on 
a Wallac WIZARD Automatic Gamma Counter. The 
protein concentration was measured on Pharmacia 
Biotech Ultraspec 3000 spectrophotometer.
Reagents
All chemicals were purchased from Sigma (EDTA, PTU, 
[125I] rT3, [125I] T4, rT3, T4, Sephadex LH-20), Merck 
(column for the purification of radioactive probes, DTT, 
TCA, BSA, EtOH, K2PO4), Pierce (BCA reagent), Gibco 
and Biomed (horse serum).
All reagents were of the highest quality and the 
procedures are widely available in publications.
Tissue homogenate solution
Tissue fragments of about 100 mg were homogenised 
in a buffer containing 1 M K2PO4, 10 mM DTT, 0.25 
M glucose and 1 mM EDTA in a teflon-glass homog-
eniser. The homogenate solution was made fresh and 
stored at –20oC.
Determination of protein concentration
Protein concentration was determined by BCA method, 
using appropriate dilutions of homogenates and bo-
vine serum albumin (BSA) as a standard. Incubation 
was performed at 37oC for 30 min and the absorbance 
measurements were carried at wavelength l = 562.
Tissue preparation
Tissues were homogenised in cold DI homogenisation 
solution at a 1:21 dilution. Homogenates were cen-
trifuged (1,500 x g) for 10 min at 4oC. Floating brush 
was removed by aspiration and the supernatant was 
aliquotted to 2 mL screw-capped tubes. Homogenates 
were recentrifuged (20,000 x g) for 5 min at 4oC, floating 
brush was removed and the supernatant decanted into 
2 mL plastic tubes and used for the DI-I assay.
Calculations
The method assumes homogeneous distribution of 125I-
labelled and nonlabelled rT3 in the incubation solution. 
Calculations were performed as follows, where: CPM 
— counts per minute; Bo — blank counts; Total — total 
counts; FV — final volume (μL); MV — measurements 
volume (μL); PC — protein concentration (g/μL); PV — 
protein volume; IT — incubation time (min).
Determination of activity of deiodinase type 1 (5’D1) 
was performed on the basis of amounts of radioactive 
iodine released from the [125I]-rT3 in deiodination re-
action, in which 5’D1 is a catalysator, according to the 
method described in [5]. On the day of the experiment, 
labelled rT3 was purified on a Sephadex LH 20, eluted 
with 75% ethanol into a series volumes of 600 μL each. 
The probe with the highest activity (50,000-60,000 cpm/ul) 
was the source of [125I]-rT3 necessary to the deiodina-
tion reaction.
The composition of the reaction mixture was: fraction 
of kidney homogenate as a source of deiodinase, [125I]-rT3, 
1 nM rT3, 20 mM DTT, 0.1 M K2PO4 buffer + 1 mM EDTA, 
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1 mM PTU. Reactions were carried out at 37°C/30 min and 
were stopped by immersing the samples in ice.
The separation of labeled iodine released from the 
iodothyronines was achieved by precipitation with 100 μL 
of horse serum and 50 μL of 50% trichloroacetic acid. Af-
ter vortexing, the probes were centrifuged and 150 μL of 
supernatant was collected for measurements of gamma 
radiation in the gamma counter.
Deiodinases specific activity was determined in 
femtomoles of released 125I per 1 mg of protein per 
1 minute [fmol 125I/mg protein/minute].
The enzymatic activity was assayed as described 
previously [5]. D1 activity was determined by quan-
tification of the radioiodine released by (125)I-rT3 in 
deiodination reaction catalysed by 5’DI according to 
the method described by Larson et al. [5]. D2 activity 
was determined by quantification of the radioiodine 
released by 3,3’,5, 125I 5’  tetraiodothyronine (T4) in 
deiodination reaction. The procedure was identical as 
for D1. In statistical analysis, Spearman’s correlation 
coefficients were used.
The research was carried out with the approval of 
the Medical University of Warsaw Bioethics Committee 
(KB/138/2005, dated 30.06.2005), supported by a grant 
from the Medical University of Warsaw (1WM1/09).
Results
Activity of D1 in renal cortex was 3.785 ± 2.041 fmol 
125I/mg protein/minute, and activity of D2 was 0.236 ± 
± 0.125 fmol 125I/mg protein/minute. There was a strong 
positive correlation between D1 and D2 activities in 
renal cortex (r = 0.890, p < 0.001).
Activity of D1 in renal medulla was 2.157 ± 2.176 
fmol 125I/mg protein/minute, and activity of D2 was 
0.168 ± 0.095 fmol 125I/mg protein/minute. A positive 
correlation between D1 and D2 in renal medulla 
(r = 0.661, p = 0.038) was observed as well.
Activities of D1 in cortex and medulla were strongly 
and positively associated (r = 0.794, p = 0.006), whereas 
there was no correlation between activities of D2 in 
cortex and medulla (r = 0.224, p = 0.553).
Discussion
It has been well proven that kidneys are able to catalyse 
the conversion of T4 to T3 [5–8]. However, the roles of 
deiodinases D1 and D2 in the human kidneys remain 
undetermined. Deiodinases are the enzymes that cata-
lyse the deiodination of thyroid hormone molecules 
(particularly T4 to T3 and T4 to rT3). As a result, they af-
fect the balance of thyroid hormones that have different 
biological activities. There has been no agreement as to 
the intracellular localisation of the enzymatic activity of 
5’-deiodinases in human kidney in the presented stud-
ies. There have been suggestions of partial microsomal 
contribution [9, 10]. The half-life of D2 in normal cells 
is 20–30 minutes in the presence of T4, whereas the D1 
protein has a longer half-life (> 12 hours).
Type 1 iodothyronine 5’-deiodinase is an integral mem-
brane protein catalysing the phenolic ring deiodination of 
thyroxine. The type 1 enzyme was present exclusively in tu-
bular epithelial cells of the outer renal cortex and co-purified 
with basolateral plasma membranes; the renal medulla lack 
of activity [11]. The results of our studies prove that there is 
an activity of type 1 deiodinase in renal medulla. It is approxi-
mately 1.8 times lower than in renal cortex (respectively 1.4 
for D2). In rat kidney studies, the activity of type 1 deiodinase 
in the proximal convoluted tubule cells and collagenases-
dispersed rat kidney cells has been found [12, 13].
Type 1 iodothyronine 5’-deiodinase (5’D-1) is 
a protein with a Mr of 29 kDa. It catalyzes the 5’-deiodi-
nation reaction of thyroxine. It takes part in the synthe-
sis  of more than 75% of the biologically active thyroid 
hormone in the circulation [14]. The biochemical and 
molecular characteristics of D2 seem to be reflecting 
extrathyroidal T3 production. Its activity is strictly 
limited by the concentration of its preferred substrate, 
T4, since it catalyses the ubiquitination of this enzyme, 
inactivating it and quickening its degradation in pro-
teasomes [15].
It is important to determine the cellular location of 
iodothyronine deiodinases since they play a significant 
role in the regulation of the available intra cellular T3 
concentration. In our study, we evaluated the activity of 
type 1 and type 2 deiodinases. However, the methodol-
ogy used in this study does not allow us to determine 
whether the activity is strictly microsomal or gener-
ally intracellular. In the kidney, the presence of type 3 
iodothyronine deiodinase (D3) seems to be crucial to 
maintain homeostasis of T3 levels. To date, no cellular 
localisation pattern of D3 protein has been determined 
in human kidneys.
It is very difficult to compare the activity of type 1 
and 2 deiodinases by performing laboratory examina-
tions, because of the different activity of their product 
(e.g. T3 v. rT3). 
Therefore, comparisons are approximate. It seems 
that the activity of deiodinases in kidneys established in 
our studies is lower than in liver and muscles indicated 
in other studies, as there are methodological differences 
[16, 17]. In chronic severe illness, a decrease is also sup-
plemented by an increase in the inner-ring deiodination 
of T4 and T3 by type 3 iodothyronine deiodinase in the 
liver and skeletal muscle [18].
There have been no previous studies addressing 
the roles of human renal iodothyronine deiodinases 
in the peripheral conversion of T4 to T3. A number of 
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studies have indicated that the expression of deiodi-
nases is altered in several types of cancers, suggesting 
that they may represent a useful cancer marker and/or 
could play a role in modulating cell proliferation [19, 20]. 
In our study, we cannot fully exclude the influence of 
renal cancer on the activity of deiodinases, despite the 
fact that material was collected from a site opposite to 
the cancer assessed by a urologist to be healthy tissue. 
In this study, we determined the activities of D1 and D2 
in renal cortex and medulla. The activity of D1 is many times 
higher than D2, both in cortex and medulla. The positive 
correlation of D1 and D2 is particularly high in renal cortex. 
We suggest that the study should be enhanced and per-
formed on a larger amount of material with methodology 
including histological differentiation of kidney structure 
and the analysis of influence of various clinical situations 
including inflammation, severity of renal failure, presence 
or absence of neoplasm, primary and secondary nephropa-
thy and influence of immunosuppressive therapy. 
It seems that loss of kidney tissue in CKD may 
lead to reported thyroid hormone disorders in CKD 
patients manifested mainly by impaired conversion of 
T4 to T3 [4].
Conclusions
The results presented in this study suggest that both 
cortical and medullary D1 and D2 may be involved in 
thyroid hormone metabolism. This finding could be 
of clinical relevance in patients with impaired renal 
function.
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